Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer

Cancer Biomarkers

Volumn 6, Issue 3-4, 2009, Pages 179-190

  Holdenrieder, Stefan ^a   Nagel, Dorothea ^a   Stieber, Petra ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

biomarker; CEA; CYFRA 21 1; cytokeratins; lung cancer; Prognosis; serum

Indexed keywords

ALBUMIN; CALCIUM; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; CYTOKERATIN 19 FRAGMENT; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEMOGLOBIN; LACTATE DEHYDROGENASE; NEURON SPECIFIC ENOLASE; SIALYL LEWIS X ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ADVANCED CANCER; CANCER SURVIVAL; DISEASE COURSE; HUMAN; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; TUMOR GROWTH; BLOOD; LUNG TUMOR; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77958162955     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2009-0128     Document Type: Review

References (105)

1. K. S. Albain, J. J. Crowley, M. LeBlanc and R. B. Livingston, Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience, J Clin Oncol 9 (1991), 1618-1626.
2. D. G. Altman, B. Lausen, W. Sauerbrei and M. Schumacher, Dangers of using optimal cutpoints in the evaluation of prognostic factors, J Natl Cancer Inst 86 (1994), 829-835.
3. D. G. Altman and G. H. Lyman, Methodological challenges in the evaluation of prognostic factors in breast cancer, Breast Cancer Res Treat 52 (1998), 289-303.
4. D. G. Altman, Systematic reviews of evaluations of prognostic variables, BMJ 323 (2001), 224-228.
5. S. Ando, H. Kimura, N. Iwai, N. Yamamoto and T. Iida, Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer, Anticancer Res 23 (2003), 2869-2874.
6. A. Ardizzoni, M. A. Cafferata, M. Paganuzzi, R. Filiberti, P. Marroni, M. Neri, V. Fontana, G. Nicolo, L. Perdelli, C. G. Stampino, R. Rosso and R. Puntoni, Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma, Cancer 92 (2001), 1896-1904.
7. A. Ardizzoni, M. A. Cafferata, M. Tiseo, R. Filiberti, P. Marroni, F. Grossi and M. Paganuzzi, Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer, Cancer 107 (2006), 2842-2849.
8. O. Arrieta, D. Saavedra-Perez, R. Kuri, A. Aviles-Salas, L. Martinez, D. Mendoza-Posada, P. Castillo, A. Astorga, E. Guzman and J. De la Garza, Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis, BMC Cancer 9 (2009), 119.
9. H. Bai, L. Mao, H. S. Wang, J. Zhao, L. Yang, T. T. An, X. Wang, C. J. Duan, N. M. Wu, Z. Q. Guo, Y. X. Liu, H. N. Liu, Y. Y. Wang and J. Wang, Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer, J Clin Oncol 27 (2009), 2653-2659.
10. V. Barak, H. Goike, K. W. Panaretakis and R. Einarsson, Clinical utility of cytokeratins as tumor markers, Clin Biochem 37 (2004), 529-540.
11. F. Barlesi, C. Gimenez, J. P. Torre, C. Doddoli, J. Mancini, L. Greillier, F. Roux and J. P. Kleisbauer, Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer, Respir Med 98 (2004), 357-362.
12. F. Barlesi, C. Tchouhadjian, C. Doddoli, J. P. Torre, P. Astoul and J. P. Kleisbauer, CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy, Br J Cancer 92 (2005), 13-14.
13. M. Bergqvist, D. Brattström, P. Hesselius, B. Wiklund, A. Silen, G. Wagenius and O. Brodin, Cytokeratin 8 and 18 fragments measured in serum and their relation to survival in patients with non-small cell lung cancer, Anticancer Res 19 (1999), 1833-1836.
14. F. Blankenburg, R. Hatz, D. Nagel, D. Ankerst, J. Reinmiedl, C. Gruber, D. Seidel and P. Stieber, Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I nonsmall cell lung cancer: external validation of a prognostic score, Tumour Biol 29 (2008), 272-277.
15. G. Buccheri, P. Torchio and D. Ferrigno, Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments, Chest 124 (Aug. 2003), 622-632.
16. C. H. Chiu, Y. N. Shih, C. M. Tsai, J. L. Liou, Y. M. Chen and R. P. Perng, Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib, Lung Cancer 57 (2007), 213-221.
17. F. de Marinis and F. Grossi, Clinical evidence for secondand third-line treatment options in advanced non-small cell lung cancer, Oncologist 13 (S1) (2008), 14-20.
18. M. Diez, A. Torres, M. L. Maestro, M. D. Ortega, A. Gomez, M. Pollan, J. A. Lopez, A. Picardo, F. Hernando and J. L. Balibrea, Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer, Br J Cancer 73 (1996), 1248-1254.
19. R. Dziadziuszko and F. R. Hirsch, Advances in genomic and proteomic studies of non-small-cell lung cancer: clinical and translational research perspective, Clin Lung Cancer 9 (2008), 78-84.
20. F. G. Ebeling, P. Stieber, M. Untch, D. Nagel, G. E. Konecny, U. M. Schmitt, A. Fateh-Moghadam and D. Seidel, Serum CEA and CA 15-3 as prognostic factors in primary breast cancer, Br J Cancer 86 (2002), 1217-1222.
21. D. S. Ettinger, G. Bepler, R. Bueno, A. Chang, J. Y. Chang, L. R. Chirieac, T. A. D'Amico, T. L. Demmy, S. J. Feigenberg, F. W. Grannis, Jr., T. Jahan, M. Jahanzeb, A. Kessinger, R. Komaki, M. G. Kris, C. J. Langer, Q. T. Le, R. Martins, G. A. Otterson, F. Robert, D. J. Sugarbaker and D. E. Wood, National Comprehensive Cancer Network (NCCN). Non-small cell lung cancer clinical practice guidelines in oncology, J Natl Compr Canc Netw 4 (2006), 548-582.
22. D. Ferrigno, G. Buccheri and C. Giordano, Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC), Lung Cancer 41 (2003), 311-320.
23. J. R. Fischer, U. Ohnmacht, N. Rieger, M. Zemaitis, C. Stoffregen, C. Manegold and H. Lahm, Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine, Lung Cancer 56 (2007), 115-123.
24. P. Foa, M. Fornier, R. Miceli, E. Seregni, L. Santambrogio, M. Nosotti, S. Massaron, I. Cataldo, S. Oldani, A. Iurlo, S. Caldiera and E. Bombardieri, Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer, Int J Biol Markers 14 (1999), 92-98.
25. G. J. Fournie, J. P. Courtin, F. Laval, J. J. Chale, J. P. Pourrat, M. C. Pujazon, D. Lauque and P. Carles, Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours, Cancer Lett 91 (1995), 221-227.
26. R. Fukai, Y. Sakao, M. Sakuraba, S. Oh, K. Shiomi, S. Sonobe, Y. Saitoh and H. Miyamoto, The prognostic value of carcinoembryonic antigen in T1N1M0 and T2N1M0 nonsmall cell carcinoma of the lung, Eur J Cardiothorac Surg 32 (2007), 440-444.
27. M. J. Gaspar, M. Diez, A. Rodriguez, T. Ratia, A. Martin Duce, M. Galvan, J. Granell and C. Coca, Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer, Anticancer Res 23 (2003), 3427-3432. (Pubitemid 36975444)
28. O. Gautschi, C. Bigosch, B. Huegli, M. Jermann, A. Marx, E. Chasse, D. Ratschiller, W. Weder, M. Joerger, D. C. Betticher, R. A. Stahel and A. Ziegler, Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy, J Clin Oncol 22 (2004), 4157-4164.
29. L. Giovanella, L. Ceriani, M. Bandera, R. Rimoldi, B. Beghe and G. Roncari, Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation, Q J Nucl Med 39 (1995), 285-289.
30. P. Goldstraw, J. Crowley, K. Chansky, D. J. Giroux, P. A. Groome, R. Rami-Porta, P. E. Postmus, V. Rusch and L. Sobin, International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours, J Thorac Oncol 2 (2007), 706-714.
31. J. Y. Han, B. G. Choi, J. Y. Choi, S. Y. Lee and S. Y. Ju, The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer, Lung Cancer 54 (2006), 227-234.
32. K. D. Hatzakis, M. E. Froudarakis, D. Bouros, N. Tzanakis, N. Karkavitsas and N. M. Siafakas, Prognostic value of serum tumor markers in patients with lung cancer, Respiration 69 (2002), 25-29.
33. D. F. Hayes, R. C. Bast, C. E. Desch, H. Fritsche, Jr., N. E. Kemeny, J. M. Jessup, G. Y. Locker, J. S. Macdonald, R. G. Mennel, L. Norton, P. Ravdin, S. Taube and R. J. Winn, Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers, J Natl Cancer Inst 88 (1996), 1456-1466.
34. H. Hemingway, R. D. Riley and D. G. Altman, Ten steps towards improving prognosis research, BMJ 339 (2009), b4184.
35. P. Hermanek and U. Mansmann, [Criteria for evaluating prognostic factors], Chirurg 72 (2001), 474-480.
36. V. Hespanhol, H. Queiroga, A. Magalhães, A. R. Santos, M. Coelho and A. Marques, Survival predictors in advanced non-small cell lung cancer, Lung Cancer 13 (1995), 253-267.
37. S. Holdenrieder, D. Nagel, V. Heinemann, J. v Pawel, H. Raith, K. Feldmann, U. H. Stenman and P. Stieber, Predictive and prognostic biomarker models in advanced lung cancer, J Clin Oncol 26 (2008), 19010 (Abs).
38. W. H. Hsu, C. S. Huang, H. S. Hsu, W. J. Huang, H. C. Lee, B. S. Huang and M. H. Huang, Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer, Ann Thorac Surg 83 (2007), 419-424.
39. W. Jacot, J. L. Pujol, J. M. Boher and P. J. Lamy, Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer, Br J Cancer 91 (2004), 430-433.
40. W. Jacot, L. Lhermitte, N. Dossat, J. L. Pujol, N. Molinari N J. P. Daurès, T. Maudelonde, A. Mangé and J. Solassol, Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes, J Thorac Oncol 3 (2008), 840-850.
41. K. Kashiwabara, H. Nakamura and T. Esaki, Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and cytokeratin 19 fragment levels, Clin Chim Acta 294 (2000), 105-113.
42. S. Kasimir-Bauer, N. Schleucher, R. Weber, R. Neumann and S. Seeber, Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival, Oncol Rep 10 (2003), 475-482.
43. N. Kobayashi, S. Toyooka, J. Soh, K. Ichimura, H. Yanai, H. Suehisa, S. Ichihara, M. Yamane, M. Aoe, Y. Sano and H. Date, Risk factors for recurrence and unfavorable prognosis in patients with stage I non-small cell lung cancer and a tumor diameter of 20 mm or less, J Thorac Oncol 2 (2007), 808-812.
44. J. Kulpa, E. Wojcik, A. Radkowski, L. Kolodziejski and Z. Stasik, CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group, Anticancer Res 20 (2000), 5035-5040.
45. J. Kulpa, E. Wojcik, M. Reinfuss and L. Kolodziejski, Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients, Clin Chem 48 (2002), 1931-1937.
46. H. Langendijk, J. de Jong, R. Wanders, P. Lambin and B. Slotman, The importance of pre-treatment haemoglobin level in inoperable non-small cell lung carcinoma treated with radical radiotherapy, Radiother Oncol 67 (2003), 321-325.
47. T. Maeda, H. Ueoka, M. Tabata, K. Kiura, T. Shibayama, K. Gemba, N. Takigawa, A. Hiraki, H. Katayama and M. Harada, Prognostic factors in advanced non-small cell lung cancer: elevated serum levels of neuron specific enolase indicate poor prognosis, Jpn J Clin Oncol 30 (2000), 534-541.
48. S. Mallett, A. Timmer, W. Sauerbrei and D. G. Altman, Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines, Br J Cancer 102 (2010), 173-180.
49. H. Matsuguma, R. Nakahara, S. Igarashi, Y. Ishikawa, H. Suzuki, N. Miyazawa, S. Honjo and K. Yokoi, Pathologic stage I non-small cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: clinicopathologic characteristics and prognosis, J Thorac Cardiovasc Surg 135 (2008), 44-49.
50. K. Matsuoka, S. Sumitomo, N. Nakashima, D. Nakajima and N. Misaki, Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I nonsmall cell lung cancer, Eur J Cardiothorac Surg 32 (2007), 435-439.
51. L. M. McShane, D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion and G. M. Clark, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (RE-MARK), J Natl Cancer Inst 97 (2005), 1180-1184.
52. T. Mitsudomi, T. Kosaka, H. Endoh, Y. Horio, T. Hida, S. Mori, S. Hatooka, M. Shinoda, T. Takahashi and Y. Yatabe, Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence, J Clin Oncol 23 (2005), 2513-2520.
53. S. Mizuguchi, N. Nishiyama, T. Iwata, T. Nishida, N. Izumi, T. Tsukioka, K. Inoue, T. Uenishi, K. Wakasa and S. Suehiro, Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer, Lung Cancer 58 (2007), 369-375.
54. R. Molina, X. Filella, J. M. Auge, R. Fuentes, I. Bover, J. Rifa, V. Moreno, E. Canals, N. Vinolas, A. Marquez, E. Barreiro, J. Borras and P. Viladiu, Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors, Tumour Biol 24 (2003), 209-218.
55. R. Molina, J. M. Auge, J. M. Escudero, R. Marrades, N. Viñolas, E. Carcereny, J. Ramirez and X. Filella, Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE, Tumour Biol 29 (2008), 371-380.
56. R. Molina, J. M. Augé, X. Bosch, J. M. Escudero, N. Viñolas, R. Marrades, J. Ramírez, E. Carcereny and X. Filella, Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology, Tumour Biol 30 (3) (2009), 121-129.
57. D. Moro, D. Villemain, J. P. Vuillez, C. A. Delord and C. Brambilla, CEA, CYFRA21-1 and SCC in non-small cell lung cancer, Lung Cancer 13 (1995), 169-176.
58. C. F. Mountain, Revisions in the international system for staging lung cacner, Chest 111 (1997), 1710-1717.
59. T. Muley, H. Dienemann and W. Ebert, Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC, Anticancer Res 23 (2003), 4085-4093.
60. T. Muley, H. Dienemann and W. Ebert, CYFRA 21-1 and CEA are independent prognostic factorsin 153operatedstage I NSCLC patients, Anticancer Res 24 (2004), 1953-1956.
61. T. Muley, T. H. Fetz, H. Dienemann, H. Hoffmann, F. J. Herth, M. Meister and W. Ebert, Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC, Lung Cancer 60 (2008), 408-415.
62. J. Niklinski, T. Burzykowski, W. Niklinska, J. Laudanski, L. Chyczewski, M. Rapellino and M. Furman, Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer, Eur Respir J 12 (1998), 1424-1428.
63. B. Nisman, J. Lafair, N. Heching, O. Lyass, M. Baras, T. Peretz and V. Barak, Evaluation of tissue polypeptide specific antigen, CYFRA 21-1 and carcinoembryonic antigen, in nonsmall cell lung carcinoma. Does the combined use of cytokeratin markers give any additional information? Cancer 82 (1998), 1850-1859.
64. B. Nisman, G. Amir, J. Lafair, N. Heching, O. Lyass, T. Peretz and V. Barak, Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer, Anticancer Res 19 (1999), 3549-3552.
65. B. Nisman, H. Biran, N. Heching, V. Barak, N. Ramu, I. Nemirovsky and T. Peretz, Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival, Br J Cancer 98 (2008), 77-79.
66. M. Okada, T. Sakamoto, W. Nishio, K. Uchino and N. Tsubota, Characteristics and prognosis of patients after resection of nonsmall cell lung carcinoma measuring 2 cm or less in greatest dimension, Cancer 98 (2003), 535-541.
67. M. Okada, W. Nishio, T. Sakamoto, K. Uchino, T. Yuki, A. Nakagawa and N. Tsubota, Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1, 000 consecutive resections for clinical stage I disease, Ann Thorac Surg 78 (2004), 216-221.
68. R. F. Ozols, R. S. Herbst, Y. L. Colson, J. Gralow, J. Bonner, W. J. Curran, Jr., B. L. Eisenberg, P. A. Ganz, B. S. Kramer, M. G. Kris, M. Markman, R. J. Mayer, D. Raghavan, G. H. Reaman, R. Sawaya, R. L. Schilsky, L. M. Schuchter, J. W. Sweetenham, L. T. Vahdat and R. J. Winn, American Society of Clinical Oncology. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology, J Clin Oncol 25 (2007), 146-162.
69. D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker, Jr., J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi and M. R. Somerfield, American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003, J Clin Oncol 22 (2004), 330-353.
70. M. Pollan, G. Varela, A. Torres, M. de la Torre, M. D. Ludena, M. D. Ortega, J. Pac, J. Freixenet, G. Gomez, F. Sebastian, M. Diez, R. Arrabal, E. Canalis, J. Garcia-Tirado, A. Arnedillo, J. J. Rivas, J. Minguella, A. Gomez, M. Garcia, N. Aragones, B. Perez-Gomez, G. Lopez-Abente, R. Gonzalez-Sarmiento and J. M. Rojas, Clinical value of p53, c-erbB-2, CEA and CA125 regarding relapse, metastasis and death in resectable non-small cell lung cancer, Int J Cancer 107 (2003), 781-790. (Pubitemid 37339732)
71. J. L. Pujol, J. Grenier, E. Parrat, M. Lehmann, T. Lafontaine, X. Quantin and F. B. Michel, Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS, Am J Respir Crit Care Med 154 (1996), 725-733.
72. J. L. Pujol, J. M. Boher, J. Grenier and X. Quantin, Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients, Lung Cancer 31 (2001), 221-231.
73. J. L. Pujol, O. Molinier, W. Ebert, J. P. Daures, F. Barlesi, G. Buccheri, M. Paesmans, E. Quoix, D. Moro-Sibilot, M. Szturmowicz, J. M. Brechot, T. Muley and J. Grenier, CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients, Br J Cancer 90 (2004), 2097-2105. (Pubitemid 38869712)
74. P. Ray, X. Quantin, J. Grenier and J. L. Pujol, Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy, Cancer Detect Prev 22 (1998), 293-304.
75. N. Reinmuth, B. Brandt, M. Semik, W. P. Kunze, R. Achatzy, H. H. Scheld, P. Broermann, W. E. Berdel, H. N. Macha and M. Thomas, Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer, Lung Cancer 36 (2002), 265-270.
76. Y. Sakao, S. Tomimitsu, Y. Takeda, M. Natsuaki and T. Itoh, Carcinoembryonic antigen as a predictive factor for postoperative tumor relapse in early-stage lung adenocarcinoma, Eur J Cardiothorac Surg 25 (2004), 520-522.
77. Y. Sakao, T. Nakazono, T. Sakuragi, M. Natsuaki and T. Itoh, Predictive factors for survival in surgically resected clinical IA peripheral adenocarcinoma of the lung, Ann Thorac Surg 77 (2004), 1157-1161.
78. S. Salmon, H. Chen, S. Chen, R. Herbst, A. Tsao, H. Tran, A. Sandler, D. Billheimer, Y. Shyr, J. W. Lee, P. Massion, J. Brahmer, J. Schiller, D. Carbone and T. P Dang, Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen, J Thorac Oncol 4 (2009), 689-696.
79. N. Sawabata, M. Ohta, S. Takeda, H. Hirano, Y. Okumura, H. Asada and H. Maeda, Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer, Ann Thorac Surg 74 (2002), 174-179.
80. N. Sawabata, H. Maeda, S. Yokota, S. Takeda, M. Koma, T. Tokunaga and M. Ito, Postoperative serum carcinoembryonic antigen levels in patients with pathologic stage IA nonsmall cell lung carcinoma: subnormal levels as an indicator of favorable prognosis, Cancer 101 (2004), 803-809.
81. A. Schalhorn, H. Fuerst and P. Stieber, Tumor markers in lung cancer, J Lab Med 25 (2001), 353-361.
82. J. Schneider, M. Philipp, H. G. Velcovsky, H. Morr and N. Katz, Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases, Anticancer Res 23 (2003), 885-893.
83. R. Simon and D. G. Altman, Statistical aspects of prognostic factor studies in oncology, Br J Cancer 69 (1994), 979-985.
84. P. Stieber, H. Dienemann, U. Hasholzner, P. G. Fabricius, C. Schambeck, M. Weinzierl, S. Poley, W. Samtleben, K. Hofmann, W. Meier etal., Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases, Int J Biol Markers 9 (1994), 82-88.
85. P. Stieber, R. Hatz, S. Holdenrieder, R. Molina, M. Nap, J. von Pawel, A. Schalhorn, J. Schneider and K. Yamaguchi, National Academy of Clinical Biochemistry Guidelines for the use of tumor markers in lung cancer. In NACB: Practice Guidelines And Recommendations For Use Of Tumor Markers In The Clinic-Lung Cancer (Section 3P). 2006; published online at www.nacb.org/lmpg/ tumor-LMPG-draft-PDF.stm.
86. H. Suzuki, S. Ishikawa, H. Satoh, H. Ishikawa, M. Sakai, T. Yamamoto, M. Onizuka and Y. Sakakibara, Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I nonsmall cell lung cancer, Eur J Cardiothorac Surg 32 (2007), 648-652.
87. F. Taguchi, B. Solomon, V. Gregorc, H. Roder, R. Gray, K. Kasahara, M. Nishio, J. Brahmer, A. Spreafico, V. Ludovini, P. P. Massion, R. Dziadziuszko, J. Schiller, J. Grigorieva, M. Tsypin, S. W. Hunsucker, R. Caprioli, M. W. Duncan, F. R. Hirsch, PA. Bunn, Jr. and D. P Carbone, Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study, J Natl Cancer Inst 99 (2007), 838-846.
88. Y. Takei, K. Minato, S. Tsuchiya, A. Takise, H. Nakano, K. Ezawa, N. Fueki, H. Hoshino, I. Naruse, T. Nomoto, T. Makimoto, S. Ishihara, R. Saito and M. Mori, CYFRA 21-1: an indicator of survival and therapeutic effect in lung cancer, Oncology 54 (1997), 43-47.
89. N. Takigawa, Y. Segawa, M. Okahara, Y. Maeda, I. Takata, M. Kataoka and M. Fujii, Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation, Lung Cancer 15 (1996), 67-77.
90. K. Takamochi, J. Yoshida, M. Nishimura, T. Yokose, S. Sasaki, Y. Nishiwaki, K. Suzuki and K. Nagai, Prognosis and histologic features of small pulmonary adenocarcinoma based on serum carcinoembryonic antigen level and computed tomographic findings, Eur J Cardiothorac Surg 25 (2004), 877-883.
91. M. Tomita, Y. Matsuzaki, M. Edagawa, T. Shimizu, M. Hara and T. Onitsuka, Prognostic significance of preoperative serum carcinoembryonic antigen level in lung adenocarcinoma but not squamous cell carcinoma, Ann Thorac Cardiovasc Surg 10 (2004), 76-80.
92. M. Tomita, Y. Matsuzaki, T. Shimizu, M. Hara, T. Ayabe and T. Onitsuka, Serum carcinoembryonic antigen level in pN1 non-small cell lung cancer patients, Anticancer Res 25 (2005), 3601-3605.
93. M. Tomita, Y. Matsuzaki, T. Shimizu, M. Hara, T. Ayabe and T. Onitsuka, Relationship between serum carcinoembryonic antigen level and T status in non-small cell lung cancer, Anticancer Res 26 (2006), 3845-3848.
94. M. Tomita, T. Shimizu, M. Hara, T. Ayabe and T. Onitsuka, Impact of preoperative hemoglobin level on survival of nonsmall cell lung cancer patients, Anticancer Res 28 (2008), 1947-1950.
95. M. Tomita, T. Shimizu, M. Hara, T. Ayabe and T. Onitsuka, Serum carcinoembryonic antigen level in non-small-cell lung cancer patients with preoperative normal serum level, Gen Thorac Cardiovasc Surg 57 (2009), 303-306.
96. J. Trape, J. Buxo, J. Perez de Olaguer and C. Vidal, Tumor markers as prognostic factors in treated non-small cell lung cancer, Anticancer Res 23 (2003), 4277-4281.
97. N. van Zandwijk, W. J. Mooi and S. Rodenhuis, Prognostic factors in NSCLC. Recent experiences, Lung Cancer 12 (S1) (1995), S27-S33.
98. T. Vassilakopoulos, T. Troupis, C. Sotiropoulou, P. Zacharatos, P. Katsaounou, D. Parthenis, O. Noussia, G. Troupis, S. Papiris, C. Kittas, C. Roussos, S. Zakynthinos and V. Gorgoulis, Diagnostic and prognostic significance of squamous cell carcinoma antigen in non-small cell lung cancer, Lung Cancer 32 (2001), 137-144.
99. G. Veronesi, G. Pelosi, A. Sonzogni, M. E. Leon, M. D'Aiuto, R. Gasparri, F. De Braud, T. De Pas, M. Sandri and L. Spaggiari, Tumour CEA as predictor of better outcome in squamous cell carcinoma of the lung, Lung Cancer 48 (2005), 233-240.
100. N. Viñolas, R. Molina, M. C. Galán, F. Casas, M. A. Callejas, X. Filella, J. J. Grau, A. M. Ballesta and J. Estape, Tumor markers in response monitoring and prognosis of nonsmall cell lung cancer: preliminary report, Anticancer Res 18 (1998), 631-634.
101. R. T. Vollmer, R. Govindan, S. L. Graziano, G. Gamble, J. Garst, M. J. Kelley and R. H. Christenson, Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response, Clin Cancer Res 9 (2003), 1728-1733.
102. J. Watine, Prognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables, Scand J Clin Lab Invest 60 (2000), 259-274.
103. J. Watine, B. Friedberg and N. Bouarioua, Biological variables and stratification of patients with inoperable non-smallcell bronchial cancer: recommendations for future trials, Cancer Radiother 6 (2002), 209-216.
104. B. Wieskopf, C. Demangeat, A. Purohit, R. Stenger, P. Gries, H. Kreisman and E. Quoix, CYFRA 21-1asabiologic marker of non-small cell lung cancer, Chest 108 (1) (1995), 163-169.
105. T. Yoshimasu, Y. Kokawa, S. Oura, I. Hirai, R. Sasaki, H. Tanino, T. Sakurai and Y. Okamura, Time course of carcinoembryonic antigen after resection of lung cancer: a predictor of recurrence, Cancer Sci 94 (2003), 741-744.